A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
2020; Springer Science+Business Media; Volume: 38; Issue: 6 Linguagem: Inglês
10.1007/s10637-020-00950-1
ISSN1573-0646
AutoresDavid A. Reardon, Annick Desjardins, Olivier Rixe, Timothy F. Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, Andrew B. Lassman,
Tópico(s)Schizophrenia research and treatment
Referência(s)